Ginwa Enterprise Group Inc Asset Resilience Ratio
Ginwa Enterprise Group Inc asset resilience ratio. Ginwa Enterprise Group Inc (600080) has an Asset Resilience Ratio of 6.26% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Ginwa Enterprise Group Inc liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Ginwa Enterprise Group Inc (1994–2025)
Asset resilience ratio of Ginwa Enterprise Group Inc from 1994 to 2025. This chart shows how Ginwa Enterprise Group Inc's Asset Resilience Ratio has changed over time. Read debt load of Ginwa Enterprise Group Inc for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Ginwa Enterprise Group Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see 600080 total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥122.81 Million | 6.26% |
| Total Liquid Assets | CN¥122.81 Million | 6.26% |
Asset Resilience Insights
- Limited Liquidity: Ginwa Enterprise Group Inc maintains only 6.26% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Ginwa Enterprise Group Inc Industry Peers by Asset Resilience Ratio
Compare Ginwa Enterprise Group Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Takeda Pharmaceutical Company Limited
F:TKDA |
Drug Manufacturers - Specialty & Generic | 0.69% |
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK |
Drug Manufacturers - Specialty & Generic | 4.94% |
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
Ajanta Pharma Limited
NSE:AJANTPHARM |
Drug Manufacturers - Specialty & Generic | 14.99% |
|
Changchun High & New Technology Industries Group Inc
SHE:000661 |
Drug Manufacturers - Specialty & Generic | 5.50% |
|
Jiangsu Nhwa Pharmaceutical Co Ltd
SHE:002262 |
Drug Manufacturers - Specialty & Generic | 26.45% |
|
Porton Fine Chemicals Ltd
SHE:300363 |
Drug Manufacturers - Specialty & Generic | 6.85% |
|
Jubilant Pharmova Limited
NSE:JUBLPHARMA |
Drug Manufacturers - Specialty & Generic | 1.26% |
Ginwa Enterprise Group Inc Asset Resilience Ratio by Year (1994–2025)
Ginwa Enterprise Group Inc asset resilience ratio by year from 1994 to 2025. The table below shows the annual Asset Resilience Ratio data for Ginwa Enterprise Group Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 2.56% | CN¥49.28 Million ≈ $7.21 Million |
CN¥1.93 Billion ≈ $282.12 Million |
+1.29pp |
| 2024-12-31 | 1.27% | CN¥25.02 Million ≈ $3.66 Million |
CN¥1.97 Billion ≈ $288.58 Million |
-1.43pp |
| 2023-12-31 | 2.70% | CN¥56.83 Million ≈ $8.32 Million |
CN¥2.11 Billion ≈ $308.55 Million |
-4.66pp |
| 2022-12-31 | 7.35% | CN¥145.14 Million ≈ $21.24 Million |
CN¥1.97 Billion ≈ $288.92 Million |
-18.86pp |
| 2021-12-31 | 26.21% | CN¥490.18 Million ≈ $71.73 Million |
CN¥1.87 Billion ≈ $273.67 Million |
+9.69pp |
| 2020-12-31 | 16.52% | CN¥323.58 Million ≈ $47.35 Million |
CN¥1.96 Billion ≈ $286.60 Million |
+12.02pp |
| 2019-12-31 | 4.50% | CN¥89.18 Million ≈ $13.05 Million |
CN¥1.98 Billion ≈ $289.71 Million |
+4.41pp |
| 2018-12-31 | 0.09% | CN¥1.78 Million ≈ $260.12K |
CN¥1.97 Billion ≈ $288.98 Million |
-0.26pp |
| 2017-12-31 | 0.35% | CN¥4.93 Million ≈ $720.75K |
CN¥1.42 Billion ≈ $207.66 Million |
-1.27pp |
| 2016-12-31 | 1.62% | CN¥23.37 Million ≈ $3.42 Million |
CN¥1.44 Billion ≈ $211.30 Million |
-1.07pp |
| 2015-12-31 | 2.69% | CN¥33.78 Million ≈ $4.94 Million |
CN¥1.26 Billion ≈ $184.10 Million |
-8.72pp |
| 2014-12-31 | 11.41% | CN¥144.50 Million ≈ $21.14 Million |
CN¥1.27 Billion ≈ $185.37 Million |
+11.38pp |
| 2005-12-31 | 0.02% | CN¥525.66K ≈ $76.92K |
CN¥2.29 Billion ≈ $334.63 Million |
-0.01pp |
| 2004-12-31 | 0.03% | CN¥567.42K ≈ $83.03K |
CN¥1.85 Billion ≈ $271.44 Million |
-0.10pp |
| 2003-12-31 | 0.13% | CN¥1.90 Million ≈ $278.03K |
CN¥1.46 Billion ≈ $214.23 Million |
0.00pp |
| 2002-12-31 | 0.13% | CN¥1.74 Million ≈ $255.26K |
CN¥1.33 Billion ≈ $195.08 Million |
-23.46pp |
| 2000-12-31 | 23.59% | CN¥244.00 Million ≈ $35.70 Million |
CN¥1.03 Billion ≈ $151.37 Million |
+12.52pp |
| 1996-12-31 | 11.07% | CN¥18.00 Million ≈ $2.63 Million |
CN¥162.65 Million ≈ $23.80 Million |
-1.99pp |
| 1995-12-31 | 13.05% | CN¥5.20 Million ≈ $760.92K |
CN¥39.83 Million ≈ $5.83 Million |
+3.71pp |
| 1994-12-31 | 9.34% | CN¥2.20 Million ≈ $321.93K |
CN¥23.54 Million ≈ $3.45 Million |
-- |
About Ginwa Enterprise Group Inc
Ginwa Enterprise (Group) Inc. researches, develops, produces, markets, and sells traditional Chinese medicines, biological drugs, and chemical drugs primarily in China. The company offers a range of orthopaedics, immunity, children, and general medicines in various dosage forms, including tablets, capsules, granules, powders, mixtures, oral solutions, syrups, and external solutions. It is also in… Read more